Flash FinanceUS
After hours S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · Ginkgo Bioworks Holdings, Inc. (DNA)

Ginkgo Bioworks Q3 revenue falls 6% to $28 million; net loss narrows to $41 million

Mixed Impact 3 of 5 earnings Written later

Ginkgo Bioworks reported third quarter 2026 revenue of $28 million, down 6% from $29 million a year earlier but up from $20 million in the second quarter. Its GAAP net loss from continuing operations narrowed to $41 million from $73 million, and Adjusted EBITDA improved to a loss of $22 million from a loss of $53 million, while the company also reaffirmed its 2026 cash burn guidance of $150 million to $125 million.

Key points

  • Q3 2026 revenue of $28 million vs. $29 million in Q3 2025, a 6% decrease
  • GAAP net loss from continuing operations of $41 million vs. $73 million a year earlier; net loss per share of $0.64 vs. $1.45
  • Adjusted EBITDA loss of $22 million vs. $53 million in the prior-year quarter; cash burn of $27 million in Q3
  • Cash and marketable securities of $285 million as of September 30, 2026; full-year 2026 cash burn guidance of ($150)-($125) million reaffirmed

The filing

CompanyGinkgo Bioworks Holdings, Inc. (DNA)
Form8-K, current report
Filed with the SECNov 5, 2026, 4:07 PM ET
Accession number0001628280-26-071022

Items reported: 2.02 Results of Operations

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 11:43 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on November 05, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.